Skip to main content

Table 2 Clinical parameters

From: Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis

  Progression to fibrosis (FP) Stable disease (SD)
n = 16 n = 20
Females 6 (38%) 11 (55%)
Age (at diagnosis, mean) 62 years 56 years
Total follow-up 75.5 years 154 years
Range 1.0–12.5 years 4.0–14.0 years
Mean follow-up 5 years 7.3 years
Hemoglobin (g/dL, median) 11.7 14.8
Leukocytes (× 106 × L−1) 16.5 9.2
Thrombocytes (× 109 × L−1) 776 912
Spleen size (mean) 13.4 cm 14.3
\